US5173298A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Nonaqueous fluorinated drug delivery vehicle suspensions
Assignee: Allergan Inc
•
Filing: 1990-09-27
•
Granted: 1992-12-22
•
Expires: 2010-09-27
Abstract
Abstract Nonaqueous pharmaceutical compositions for use in aqueous physiological systems are disclosed comprising drug delivery vehicles suspended in nonaqueous perfluorocarbon or fluorinated silicone liquid carriers. The suspended drug delivery vehicles may be water labile or water stable and incorporate therapeutic or diagnostic compounds which remain stable and pharmaceutically effective for extended periods. The pharmaceutical compositions possess extended shelf-lives and do not leach the incorporated therapeutic or diagnostic compounds into the liquid carriers making them well suited for multi-dose packaging and administration.
Inventors
- 👤 David L. Meadows
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 13:30
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0026; A61K31/00; A61K31/02; A61K31/025; A61K9/0048; A61K9/10; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1635
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
45 words
A pharmaceutical composition comprising: a nonaqueous fluorinated liquid carrier selected from the group consisting of polyfluoroalkylmethylsiloxanes; and at least one polymeric drug delivery vehicle suspended in said nonaqueous liquid carrier, said drug delivery vehicle incorporating a pharmaceutically effective amount of a therapeutic or diagnostic compound.
Claim 2
Dependent Claim
45 words
A pharmaceutical composition comprising: a nonaqueous fluorinated liquid carrier selected from the group consisting of polyfluoroalkylmethylsiloxanes; and at least one polymeric drug delivery vehicle suspended in said nonaqueous liquid carrier, said drug delivery vehicle incorporating a pharmaceutically effective amount of a therapeutic or diagnostic compound.
Claim 3
Dependent Claim
11 words
The pharmaceutical composition of claim 1 wherein said polyfluoromethylsiloxane is polytrifluoropropylmethylsiloxane.
Claim 4
Dependent Claim
73 words
A shelf-stable liquid suspension pharmaceutical composition comprising: a nonaqueous physiologically acceptable fluorinated liquid carrier selected from the group consisting of perfluorocarbons and fluorinated silicones; and at least one water stable polymeric drug delivery vehicle suspended in said nonaqueous fluorinated liquid carrier, said water stable polymeric drug delivery vehicle selected from the group consisting of acrylate, ethylene vinylacetate, silicones, polyurethanes, and polysulfones and incorporating a pharmaceutically effective amount of a therapeutic or diagnostic compound.
Claim 5
Dependent Claim
73 words
A shelf-stable liquid suspension pharmaceutical composition comprising: a nonaqueous physiologically acceptable fluorinated liquid carrier selected from the group consisting of perfluorocarbons and fluorinated silicones; and at least one water stable polymeric drug delivery vehicle suspended in said nonaqueous fluorinated liquid carrier, said water stable polymeric drug delivery vehicle selected from the group consisting of acrylate, ethylene vinylacetate, silicones, polyurethanes, and polysulfones and incorporating a pharmaceutically effective amount of a therapeutic or diagnostic compound.
Claim 6
Dependent Claim
77 words
A shelf-stable liquid suspension pharmaceutical composition comprising: a plurality of microparticulates suspended in a physiologically acceptable perfluorocarbon liquid carrier, each of said microparticulates sized from approximately 2 microns to 200 microns and incorporating a pharmaceutically effective amount of a therapeutic or diagnostic compound, each of said microparticulates formed of polymeric material selected from the group consisting of acrylate, ethylene vinylacetate, silicones, polyurethanes, poly(methylvinylether/maleic anhydride), polyorthoesters, polyvinylpyrrolidone, polysebacic acid anhydride, polycarboxyphenoxypropane anhydride, polyterephthalic acid anhydride, polyphosphazine and polysulfones.
Claim 7
Dependent Claim
77 words
A shelf-stable liquid suspension pharmaceutical composition comprising: a plurality of microparticulates suspended in a physiologically acceptable perfluorocarbon liquid carrier, each of said microparticulates sized from approximately 2 microns to 200 microns and incorporating a pharmaceutically effective amount of a therapeutic or diagnostic compound, each of said microparticulates formed of polymeric material selected from the group consisting of acrylate, ethylene vinylacetate, silicones, polyurethanes, poly(methylvinylether/maleic anhydride), polyorthoesters, polyvinylpyrrolidone, polysebacic acid anhydride, polycarboxyphenoxypropane anhydride, polyterephthalic acid anhydride, polyphosphazine and polysulfones.
Claim 8
Independent Claim
77 words
A method for delivering pharmaceutical compounds to an aqueous physiologic target site, said method comprising the steps of: providing a pharmaceutical composition formed of a nonaqueous physiologically acceptable fluorinated liquid carrier selected from the group consisting of physiologically acceptable polyfluoroalkylmethylsiloxanes and at least one water labile polymeric drug delivery vehicle suspended therein, said drug delivery vehicle incorporating at least one pharmaceutical compound; and administering a pharmaceutically effective amount of said pharmaceutical composition to said physiologic target site.
Claim 9
Independent Claim
77 words
A method for delivering pharmaceutical compounds to an aqueous physiologic target site, said method comprising the steps of: providing a pharmaceutical composition formed of a nonaqueous physiologically acceptable fluorinated liquid carrier selected from the group consisting of physiologically acceptable polyfluoroalkylmethylsiloxanes and at least one water labile polymeric drug delivery vehicle suspended therein, said drug delivery vehicle incorporating at least one pharmaceutical compound; and administering a pharmaceutically effective amount of said pharmaceutical composition to said physiologic target site.
Claim 10
Dependent Claim
12 words
The method of claim 5 wherein said target site is the eye.
References Cited (Backward Citations)
US3911138A
Cited
US3911138B1
Cited
US4105798A
Cited
US4115544A
Cited
US4366169A
Cited
US4452818A
Cited
EP0089815B1
Cited
EP0091313B1
Cited
US4649047A
Cited
EP0288659A1
Cited
US4865846A
Cited
US4882150A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-12-22 | 1996-06-22 | 1996-12-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-12-22 | 2000-06-22 | 2000-12-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-12-22 | 2004-06-22 | 2004-12-22 | $7700.00 | Window Closed / Lapsed |